South Korea Designates 5 New Drugs, Including Synthetic Marijuana and LSD

Innovation by 2FIRSTS.ai
Dec.13.2023
South Korea Designates 5 New Drugs, Including Synthetic Marijuana and LSD
South Korea designates 5 new substances, including synthetic cannabis and LSD, as new drugs; customs intercept 35 related cases.

According to a report by KIHOILBO, South Korea has officially identified and classified four synthetic marijuana series and one LSD series, totaling five substances, as new types of drugs.

 

Customs at Incheon International Airport have successfully intercepted five new types of domestically imported drugs in the past two years that have altered the existing chemical structure of illicit substances and possess similar effects but are not regulated by law. In June of this year, customs authorities confirmed through meticulous analysis that e-cigarette liquid smuggled into the country from Vietnam contained 'MDMB-INACA,' a compound resembling synthetic marijuana.

 

In the following two years, customs authorities have discovered four types of synthetic marijuana series with hallucinogenic effects and high addictive potential ('MDMB-INACA', 'ADB-INACA', '5C-MDA-19', 'ADB-FUBIATA'), as well as one type of LSD series ('1V-LSD') which is known to cause severe physical and psychological dependence after misuse.

 

Customs has submitted a request to the South Korean Food and Drug Safety Agency to designate these new types of drugs as controlled substances. Recently, the Food and Drug Safety Agency has officially designated these substances as new types of drugs.

 

After the designation of these new drugs, Incheon Airport Customs has successfully identified 35 cases of crimes related to the new drugs, including 17 cases of the new drug 'ADB-FUBIATA,' 13 cases of 'MDMB-INACA,' 3 cases of 'ADB-INACA,' 1 case of '1V-LSD,' and 1 case of '5C-MDA-19'.

 

Customs officials at Incheon Airport stated that they will collaborate closely with relevant departments to prevent the domestic entry of drugs, ensuring social security and safeguarding public health. Customs will also take the strictest measures to combat criminal activities involving new types of drugs.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
The European Patent Office (EPO) published an appeal decision on November 17, 2026, revoking Philip Morris Products S.A.'s European nicotine pouch patent EP 3773494, covering a formulation involving free-base nicotine, ion-exchange resin and a water content of at least 15%. The decision followed an opposition and appeal brought by British American Tobacco (BAT) entity Nicoventures Trading Limited. Philip Morris withdrew its approval of the patent text during the appeal, leading the EPO to revoke the patent. A separate European patent, EP 3809884, covering the distribution of nicotine between a pouch membrane and its internal composition, had been revoked on September 24 following a challenge from another BAT entity. The patents share a 2019 priority basis, while related European divisional applications also exist.
company
Nov.18 by 2Firsts Perspectives
Iowa Vape Directory Exposes Retail Divide: Specialty Vape Retailer Route 69 Vapor Says Over 98% of Its Inventory Is Unlisted, While Convenience Chains Casey’s, Maverik and Tobacco Giant Altria Previously Backed the Law
Iowa Vape Directory Exposes Retail Divide: Specialty Vape Retailer Route 69 Vapor Says Over 98% of Its Inventory Is Unlisted, While Convenience Chains Casey’s, Maverik and Tobacco Giant Altria Previously Backed the Law
Iowa published its first vapor products directory on November 16, 2026, restricting retail sales to products covered by 361 listed entries. In interviews published on November 18, independent vape retailers described inventory restrictions, revenue exposure and store closure plans. Route 69 Vapor said more than 98% of its inventory was excluded from the directory, while Central Iowa Vapors said approximately 91% of its existing product assortment was unlisted. A mixed tobacco retailer reported nearly $15,000 in vape inventory that suppliers would not accept for return. Iowa legislative records show that convenience store and fuel retail chains Casey’s and Maverik, along with tobacco company Altria, supported the legislation establishing the directory in 2024. The new rules also affect licensed distributors, wholesalers and manufacturers, bringing supply-chain arrangements into the dispute over retail access.
Regulations
Nov.19
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Philip Morris Japan (PMJ) began launching three IQOS ILUMA i BEYOND limited-edition heated tobacco devices in Japan on November 18, 2026, covering PRIME, the standard ILUMA i and ONE. Suggested retail prices are ¥11,980, ¥7,980 and ¥4,980, respectively, matching the REMIX limited-edition collection introduced in June. BEYOND features blue finishes, translucent components and differentiated surface materials while retaining the existing IQOS ILUMA i device architecture. As with REMIX, all three models are available through official and specialist retail channels, while the subsequent convenience store rollout covers only the standard ILUMA i and ONE versions. The two collections share the same pricing tiers and retail distribution structure, with their principal differences in exterior design.
product
Nov.20
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
AIR Global PLC (NASDAQ: AIIR) announced on November 5, 2026, that it had submitted a Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) for Crown Switch, its rechargeable pod vape platform. First launched in Germany in November 2025, the device uses Quantum Chip atomization technology developed by Canadian vaporization technology company Greentank Innovations. German retail versions feature 2mL prefilled pods containing 18mg/mL nicotine in six flavors, while AIR has separately tested two 5% nicotine formulations intended for U.S. development. AIR invested $20 million in Greentank in July and reported approximately $3.4 million in U.S. PMTA-related regulatory costs for the first nine months of 2026. The Crown Switch application has been submitted, but the FDA has not granted marketing authorization.
product
Nov.13
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Four CrossBar 20K disposable e-cigarettes appeared on Pennsylvania's 163-entry ENDS directory ahead of enforcement beginning October 19, 2026. The devices feature 13mL e-liquid reservoirs, 50mg/mL nicotine, 2,000mAh batteries and 0.9Ω mesh coils, with advertised puff counts of up to 20,000. CrossBar was the only modern high-puff disposable series among the directory's 15 disposable entries. Its packaging emphasizes New York design and Japanese-origin flavoring, while historical CrossBar records identify a registered U.S. tobacco manufacturing-related establishment. The link between the newer 13mL devices and earlier 1.3mL PMTA filings remains unconfirmed.
product
Oct.26